The 4th Protein Discovery and Therapeutics

The Annual Protein Discovery and Therapeutics conference will take place on October 19-21, 2011 in at Paradise Point Resort & Spa in San Diego, CA. It will enable the discussion of how antibody and alternative protein therapeutics provide the pharmaceutical industry with solutions to conditions and diseases beyond what small molecule drug discovery can offer. The conference will also delve into how this promise and potential come with a large price tag, and will discuss novel targets and methods, alternatives to conventional antibody engineering, regulations and patent law. These discussions are conducted in an intimate setting that allows for networking and interaction among attendees and speakers at the conference.

Topics that will be covered at the conference include The Future of Protein Discovery, which will delve into bi-specific and multi-specific fusion proteins, modified proteins and antibodies, antibody drug conjugates, biosimilars and biosuperiors. Also covered at the conference will be Novel Alternative Protien Therapeutics, such as non-IG scaffolds, antibody fragments, new peptide approaches in pharmacotherapeutic development, and nutraceuticals. Overcoming Challenges in Protein Therapeutics will touch upon the steps in the discovery process: advances in expression systems, immunogenicity, aggregation, subvisible particles, stability, and delivery. The final step, patenting a protein therapeutic, will be addressed in a featured presentation by Susan Alpert Seigel and William D. Noonan of Klarquist Sparkman LLP.

The plenary keynote session features J. Carmel Egan, Vice President of Eli Lilly and Company, William R. Strohl, Vice President at Johnson and Johnson, Barry A. Morgan, Vice President at GlaxoSmithKline, Martin Edwards, Vice Presdient at Pfizer Global Research and Development, and Glenn D. Prestwich, President Professor at University of Utah. Some of the companies represented include Novartis, Roche Diagnostics GmbH, Zyngenia, Micromet AG, Anaptysbio, Nektar Therapeutics, NovImmune SA, Ambrx, Affibody, RC Tech and Merus Biopharmaceuticals. Academic and government organizations, such as the National Center Institute, Scripps Research Institute and Albany Medical College will also be represented.

The topics to be covered at the conference are Vaccines for Infectious diseases, including Dengue vaccines, HIV vaccines, Mucosal vaccines, and Malaria Vaccines. Therapeutic Vaccines will cover cancer vaccines and Alzheimer’s vaccines. Regulatory and Government Policy will cover U.S. National Vaccine Plan, government regulations, and animal rule. New Technologies in Vaccine Development will cover adjuvants, MIMIC, synthetic VLPs, among others. The conference will also address the Future Trends of Vaccine Discovery and New Vaccines, which will delve into Nisseria and nanoparticles.